Cp40 reverses periodontitis

George Hajishengallis, Thomas W. Evans Centennial Professor at the School of Dental Medicine at the University of Pennsylvania, gave an interview to regarding the potential for Cp40 to serve as an adjunctive therapy to the management of human chronic periodontitis. He discussed a current study, the result of eight years of collaboration with Dr. John D. Lambris, in which the C3 inhibitor Cp40 was administered to the periodontal tissue just once a week and was found to reverse naturally occurring chronic periodontitis in a preclinical model. The researchers found that Cp40 inhibited pre-existing gingival inflammation (as determined by both clinical and laboratory assessment) and the formation of osteoclasts, which are the cells involved in the resorption of bone. Hajishengallis further discussed recommendations for future studies.

To read entire interview: